Safety of tocilizumab in rheumatoid arthritis patients with resolved hepatitis B virus infection

Data from real-world experience

Sung Soo Ahn, Seung Min Jung, Jason Jungsik Song, YongBeom Park, Junyong Park, Sang Won Lee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

To investigate whether the use of IL-6 receptor antagonist (tocilizumab) might be associated with hepatitis B virus (HBV) reactivation in rheumatoid arthritis (RA) patients, particularly in those with resolved HBV infection [HBV surface antigen (HBsAg) negative and antibody to HBV core antigen (anti-HBc) positive, serologically]. HBsAg, anti-HBc, antibody to HBsAg (anti-HBs), and HBV DNA titers were measured in RA patients who had continuously received tocilizumab for more than 3 months. Patients were divided into two groups according to the presence of anti-HBc. Clinical and laboratory data, in addition to medications administered along with tocilizumab during the treatment duration with tocilizumab, were compared between the two groups. HBV reactivation was defined as the presence of HBV DNA in sera, and alterations in HBsAg, anti-HBc, and anti-HBs titers according to the use of tocilizumab were also evaluated. Fifteen of 39 patients (38.5%) had anti-HBc positivity, while 24 patients (61.5%) did not. There were no differences in demographic data, serologic classification, and variables related to tocilizumab between the anti-HBc-positive and -negative groups. Comparison of the medications administered along with tocilizumab treatment revealed no meaningful differences. None of the patients experienced reactivation of HBV. In addition, in 15 patients with resolved HBV infection, no alterations in HBsAg, anti-HBc, and anti-HBs titers were observed with the use of tocilizumab. Tocilizumab may be applied to RA patients safely with few concerns for HBV reactivation, particularly in those with resolved HBV infection.

Original languageEnglish
Pages (from-to)452-456
Number of pages5
JournalYonsei medical journal
Volume59
Issue number3
DOIs
Publication statusPublished - 2018 May 1

Fingerprint

Virus Diseases
Hepatitis B virus
Rheumatoid Arthritis
Safety
Surface Antigens
Antibodies
Antigens
tocilizumab
Hepatitis B Core Antigens
Interleukin-6 Receptors
DNA
Hepatitis B Surface Antigens
Viral Load
Demography

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{ab53b74ba4d3467bb4d843fb46e40b10,
title = "Safety of tocilizumab in rheumatoid arthritis patients with resolved hepatitis B virus infection: Data from real-world experience",
abstract = "To investigate whether the use of IL-6 receptor antagonist (tocilizumab) might be associated with hepatitis B virus (HBV) reactivation in rheumatoid arthritis (RA) patients, particularly in those with resolved HBV infection [HBV surface antigen (HBsAg) negative and antibody to HBV core antigen (anti-HBc) positive, serologically]. HBsAg, anti-HBc, antibody to HBsAg (anti-HBs), and HBV DNA titers were measured in RA patients who had continuously received tocilizumab for more than 3 months. Patients were divided into two groups according to the presence of anti-HBc. Clinical and laboratory data, in addition to medications administered along with tocilizumab during the treatment duration with tocilizumab, were compared between the two groups. HBV reactivation was defined as the presence of HBV DNA in sera, and alterations in HBsAg, anti-HBc, and anti-HBs titers according to the use of tocilizumab were also evaluated. Fifteen of 39 patients (38.5{\%}) had anti-HBc positivity, while 24 patients (61.5{\%}) did not. There were no differences in demographic data, serologic classification, and variables related to tocilizumab between the anti-HBc-positive and -negative groups. Comparison of the medications administered along with tocilizumab treatment revealed no meaningful differences. None of the patients experienced reactivation of HBV. In addition, in 15 patients with resolved HBV infection, no alterations in HBsAg, anti-HBc, and anti-HBs titers were observed with the use of tocilizumab. Tocilizumab may be applied to RA patients safely with few concerns for HBV reactivation, particularly in those with resolved HBV infection.",
author = "Ahn, {Sung Soo} and Jung, {Seung Min} and Song, {Jason Jungsik} and YongBeom Park and Junyong Park and Lee, {Sang Won}",
year = "2018",
month = "5",
day = "1",
doi = "10.3349/ymj.2018.59.3.452",
language = "English",
volume = "59",
pages = "452--456",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "3",

}

Safety of tocilizumab in rheumatoid arthritis patients with resolved hepatitis B virus infection : Data from real-world experience. / Ahn, Sung Soo; Jung, Seung Min; Song, Jason Jungsik; Park, YongBeom; Park, Junyong; Lee, Sang Won.

In: Yonsei medical journal, Vol. 59, No. 3, 01.05.2018, p. 452-456.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Safety of tocilizumab in rheumatoid arthritis patients with resolved hepatitis B virus infection

T2 - Data from real-world experience

AU - Ahn, Sung Soo

AU - Jung, Seung Min

AU - Song, Jason Jungsik

AU - Park, YongBeom

AU - Park, Junyong

AU - Lee, Sang Won

PY - 2018/5/1

Y1 - 2018/5/1

N2 - To investigate whether the use of IL-6 receptor antagonist (tocilizumab) might be associated with hepatitis B virus (HBV) reactivation in rheumatoid arthritis (RA) patients, particularly in those with resolved HBV infection [HBV surface antigen (HBsAg) negative and antibody to HBV core antigen (anti-HBc) positive, serologically]. HBsAg, anti-HBc, antibody to HBsAg (anti-HBs), and HBV DNA titers were measured in RA patients who had continuously received tocilizumab for more than 3 months. Patients were divided into two groups according to the presence of anti-HBc. Clinical and laboratory data, in addition to medications administered along with tocilizumab during the treatment duration with tocilizumab, were compared between the two groups. HBV reactivation was defined as the presence of HBV DNA in sera, and alterations in HBsAg, anti-HBc, and anti-HBs titers according to the use of tocilizumab were also evaluated. Fifteen of 39 patients (38.5%) had anti-HBc positivity, while 24 patients (61.5%) did not. There were no differences in demographic data, serologic classification, and variables related to tocilizumab between the anti-HBc-positive and -negative groups. Comparison of the medications administered along with tocilizumab treatment revealed no meaningful differences. None of the patients experienced reactivation of HBV. In addition, in 15 patients with resolved HBV infection, no alterations in HBsAg, anti-HBc, and anti-HBs titers were observed with the use of tocilizumab. Tocilizumab may be applied to RA patients safely with few concerns for HBV reactivation, particularly in those with resolved HBV infection.

AB - To investigate whether the use of IL-6 receptor antagonist (tocilizumab) might be associated with hepatitis B virus (HBV) reactivation in rheumatoid arthritis (RA) patients, particularly in those with resolved HBV infection [HBV surface antigen (HBsAg) negative and antibody to HBV core antigen (anti-HBc) positive, serologically]. HBsAg, anti-HBc, antibody to HBsAg (anti-HBs), and HBV DNA titers were measured in RA patients who had continuously received tocilizumab for more than 3 months. Patients were divided into two groups according to the presence of anti-HBc. Clinical and laboratory data, in addition to medications administered along with tocilizumab during the treatment duration with tocilizumab, were compared between the two groups. HBV reactivation was defined as the presence of HBV DNA in sera, and alterations in HBsAg, anti-HBc, and anti-HBs titers according to the use of tocilizumab were also evaluated. Fifteen of 39 patients (38.5%) had anti-HBc positivity, while 24 patients (61.5%) did not. There were no differences in demographic data, serologic classification, and variables related to tocilizumab between the anti-HBc-positive and -negative groups. Comparison of the medications administered along with tocilizumab treatment revealed no meaningful differences. None of the patients experienced reactivation of HBV. In addition, in 15 patients with resolved HBV infection, no alterations in HBsAg, anti-HBc, and anti-HBs titers were observed with the use of tocilizumab. Tocilizumab may be applied to RA patients safely with few concerns for HBV reactivation, particularly in those with resolved HBV infection.

UR - http://www.scopus.com/inward/record.url?scp=85045026109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045026109&partnerID=8YFLogxK

U2 - 10.3349/ymj.2018.59.3.452

DO - 10.3349/ymj.2018.59.3.452

M3 - Article

VL - 59

SP - 452

EP - 456

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 3

ER -